STOCK TITAN

Marinus Pharmaceuticals Inc - MRNS STOCK NEWS

Welcome to our dedicated news page for Marinus Pharmaceuticals (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marinus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marinus Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.11%
Tags
offering
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.11%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.11%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Marinus Pharmaceuticals Inc

Nasdaq:MRNS

MRNS Rankings

MRNS Stock Data

493.97M
42.71M
1.52%
99.15%
6.54%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Radnor

About MRNS

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides